Brighton, MI, United States of America

Jeffery David Scholten


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1999-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jeffery David Scholten

Introduction: Jeffery David Scholten, an inventive mind based in Brighton, Michigan, has made significant strides in the field of biomedical research. With three patents to his name, Scholten's work focuses on developing compounds that inhibit amyloidosis, a condition closely associated with Alzheimer's disease.

Latest Patents: Scholten's latest innovations include two notable patents. The first patent discusses the use of naphthylazo compounds to inhibit amyloid aggregation in animals. The innovative formula specified involves various substituent groups, allowing for tailored applications in preventing and treating Alzheimer's disease. The second patent details the inhibition of amyloidosis by 9-acridinones, further demonstrating his commitment to addressing neurological conditions.

Career Highlights: Scholten is affiliated with Warner-Lambert Company, a prominent player in the pharmaceutical industry. His contributions to the field of healthcare underscore his role as an impactful inventor dedicated to improving patient care through innovative solutions.

Collaborations: Throughout his career, Jeffery David Scholten has collaborated with other knowledgeable professionals, including Sheryl Jeanne Hays and Harry LeVine, III. These partnerships signify the importance of teamwork in fostering innovation and achieving groundbreaking results in research and development.

Conclusion: In conclusion, Jeffery David Scholten stands out as an influential inventor striving to combat amyloidosis and improve the lives of individuals affected by Alzheimer’s disease. His patents reflect a significant contribution to pharmaceutical research, showcasing his dedication to innovation and collaboration within the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…